(Q28264862)

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Kurtzke scales revisited: the application of psychometric methods to clinical intuition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

An assessment of disability rating scales used in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Effect of relapses on development of residual deficit in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Assessing disability progression with the Multiple Sclerosis Functional Composite

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Assessing functional status: exploring the relationship between the multiple sclerosis functional composite and driving

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Paced auditory serial-addition task: a measure of recovery from concussion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Cognitive impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Risk factors for and management of cognitive dysfunction in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Paced visual serial addition test in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Optimal reference population for the multiple sclerosis functional composite

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Quantitative functional measures in MS: what is a reliable change?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Disease activity free status in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Cerebral vascular accidents in patients over the age of 60. II. Prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

The role of affect on the perception of disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Measuring the impact of multiple sclerosis on psychosocial functioning: the development of a new self-efficacy scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

The PHQ-9: validity of a brief depression severity measure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-¹¹C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

Biomarkers of disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021

The FDA critical path initiative and its influence on new drug development.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970059-5

7 January 2021